NASDAQ:LSTA

Lisata Therapeutics Q3 2026 Earnings Results & Report

Lisata Therapeutics logo
$1.04 -0.05 (-4.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.04 0.00 (0.00%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lisata Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.73 versus the -$1.1250 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Lisata Therapeutics EPS Results

Actual EPS
-$0.73
Consensus EPS
-$1.1250
Beat/Miss
Beat by +$0.3950
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Lisata Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$659 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Lisata Therapeutics Q3 2026 Earnings FAQ

Lisata Therapeutics (NASDAQ:LSTA) reported earnings of -$0.73 per share for Q3 2026, beating the consensus estimate of -$1.1250. The report was announced on Friday, November 13, 2026.

Lisata Therapeutics Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Critical Comparison: Lisata Therapeutics (LSTA) and Its Competitors
See More Lisata Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lisata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lisata Therapeutics and other key companies, straight to your email.

About Lisata Therapeutics

Lisata Therapeutics (NASDAQ:LSTA) is a clinical-stage biopharmaceutical company developing therapies for cancer and other serious diseases. The company’s research focuses on improving the delivery of treatments to solid tumors.

Its lead investigational product, certepetide (also known as LSTA1 or CEND-1), is a peptide being studied in combination with existing cancer therapies. Clinical development has included pancreatic cancer and other solid tumors; certepetide is not an approved commercial treatment.

Lisata adopted its current name in 2022 following a merger involving Cend Therapeutics and the former Caladrius Biosciences. The company is based in Basking Ridge, New Jersey.

View Lisata Therapeutics Profile